CD274 and head and neck squamous cell carcinoma: The authors show that monotherapy with immune checkpoint blockers (ICBs) targeting PD‐L1 induces global changes in the tumor microenvironment (TME) in head and neck squamous cell carcinoma (HNSCC) in which PD‐L1 is highly expressed.